Search results
Clinical-stage gene therapy company focused on neurodegeneration
- Sio Gene Therapies (OTC:SIOX) is a clinical-stage gene therapy company focused on neurodegeneration. The company was founded in 2014, originally named Axovant, as a Roivant company to develop new medicines for Alzheimer’s. After a clinical failure, the company made a pivot to gene therapies.
seekingalpha.com › article › 4431842-sio-gene-therapies-gene-therapies-for-neurodegeneration
Sio Gene Therapies is a clinical-stage company with a singular focus on pushing the boundaries of gene therapy to develop treatments for debilitating rare neurodegenerative diseases, including GM1 gangliosidosis and Tay-Sachs/Sandhoff disease.
Sio Gene Therapies, Inc. was a biotechnology company that developed gene therapies for rare diseases. It ceased operations and dissolved in April 2023 after a stockholder vote.
Sio Gene Therapies, Inc. (formerly known as Axovant Gene Therapies) was a clinical-stage pharmaceutical company that developed gene therapies to treat neurological disorders. The company was headquartered in New York City and was incorporated in Basel, Switzerland.
Dec 15, 2022 · Following a monthslong business review, Sio Gene Therapies revealed Thursday plans to shut down the company and liquidate its assets. The plan, put forward by the company’s board of directors, will need to win shareholder approval at a meeting slated to take place in the first quarter.
Oct 21, 2021 · Sio Gene Therapies Announces Positive Interim Safety and Biomarker Data from Ongoing Phase 1/2 Clinical Study of AXO-AAV-GM1 Gene Therapy in GM1 Gangliosidosis. October 21, 2021 05:30 ET |...
- 13.7M
- 877-407-0792
- 201-689-8263
Oct 21, 2021 · NEW YORK and DURHAM, N.C., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to radically transform the...
Nov 1, 2021 · NEW YORK and DURHAM, N.C., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to radically transform the...
